He says that Aseir, a company he founded to sell a hair regrowth bioregulator product, was completely blocked by Big Pharma in its ad efforts because in the cold traffic space of Facebook and Google and now Instagram, they would not allow any kind of peptide-based hair regrowth product to gain any kind of market for more penetration. Campbell says that Big Pharmas influence and insane amounts of money has given it a lot of control over cold traffic marketing
GLP-3 Program: Maximum Support First Month: $249 (regularly $349), then $349/month ongoing
Psychopharmacology 241, 315326
GHK-Cu also restores antioxidant defenses by upregulating Nrf2 expression, which is crucial for combating oxidative damage in COPD 7
revenue generated by GLP-1 products from launch through 2024 in comparison to the total combined gain in market capitalization for Eli Lilly and Novo Nordisk since the first product launch for each company (Ozempic 12/5/17 and Mounjaro 5/13/22) and through the end of 2024
[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Kouidrat Y., Pizzol D., Cosco T., Thompson T., Carnaghi M., Bertoldo A., Solmi M., Stubbs B., Veronese N